Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine

Oncology Reports

Volumn 30, Issue 2, 2013, Pages 773-782

  Xie, Xia ^a   Tang, Bo ^a   Zhou, Jianyun ^a   Gao, Qing ^b   Zhang, Pengbing ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Gastric cancer; LY294002; Multidrug resistance; Phosphatidylinositol 3 kinase Akt; Vincristine

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CASPASE 3; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; VINCRISTINE; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG POTENTIATION; ENZYME INHIBITION; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; UPREGULATION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL LINE, TUMOR; CELL SURVIVAL; CHROMONES; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; MALE; MICE; MICE, NUDE; MORPHOLINES; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; VINCRISTINE; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84879682726     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2520     Document Type: Article

References (47)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Plummer M, Franceschi S and Muñoz N: Epidemiology of gastric cancer. IARC Sci Publ 157: 311-326, 2004.
3. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F and Van Cutsem E: Gastric cancer. Crit Rev Oncol Hematol 71: 127-164, 2009.
4. Ozeben T: Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett 580: 2903-2909, 2006.
5. Gillet JP and Gottesman MM: Mechanisms of multidrug resistance in cancer. Methods Mol Biol 596: 47-76, 2010.
6. Gillet JP, Efferth T and Remacle J: Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 1775: 237-262, 2007. (Pubitemid 46899341)
7. Callaghan R, Crowley E, Potter S and Kerr ID: P-glycoprotein: so many ways to turn it on. J Clin Pharmacol 48: 365-378, 2008.
8. Martin LP, Hamilton TC and Schilder RJ: Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 14: 1291-1295, 2008. (Pubitemid 351413906)
9. Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M and Wick W: Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res 14: 2900-2908, 2008.
10. Rodriguez-Nieto S and Zhivotovsky B: Role of alterations in the apoptotic machinery in sensitivity of cancer cells to treatment. Curr Pharm Des 12: 4411-4425, 2006. (Pubitemid 44835154)
11. Viktorsson K, Lewensohn R and Zhivotovsky B: Apoptotic pathways and therapy resistance in human malignancies. Adv Cancer Res 94: 143-196, 2005. (Pubitemid 41213078)
12. Kim D, Dan HC, Park S, Yang L, Liu Q, Kaneko S, Ning J, He L, Yang H, Sun M, Nicosia SV and Cheng JQ: AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci 10: 975-987, 2005.
13. Liu P, ChenG H, Roberts TM and Zhao JJ: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8: 627-644, 2009.
14. Courtney KD, Corcoran RB and Engelman JA: The PI3K pathway as drug target in human cancer. J Clin Oncol 28: 1075-1083, 2010.
15. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30: 193-204, 2004.
16. Kunnimalaiyaan M, Ndiaye M and Chen H: Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002. Surgery 140: 1009-1014, 2006.
17. Liu P, Xu B, Li J and Lu H: LY294002 inhibits leukemia cell invasion and migration through early growth response gene 1 induction independent of phosphatidylinositol 3-kinase-Akt pathway. Biochem Biophys Res Commun 377: 187-190, 2008.
18. Imai Y, Yoshimori M, Fukuda K, Yamagishi H and Ueda Y: The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation. Oncol Rep 27: 1703-1709, 2012.
19. Wu D, Tao J, Xu B, Qing W, Li P, Lu Q and Zhang W: Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells. Urol Int 87: 105-113, 2011.
20. + T cells and enables CpG oligodeoxynucleotide-mediated costimulation. Immunity 25: 783-793, 2006.
21. Crowell JA, Steele VE and Fay JR: Targeting the AKT protein kinase for cancer chemoprevention. Mol Cancer Ther 6: 2139-2148, 2007. (Pubitemid 47294742)
22. Hennessy BT, Smith DL, Ram PT, Lu Y and Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004, 2005.
23. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin III EF and Liotta LA: Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20: 1981-1989, 2001. (Pubitemid 32458030)
24. García MG, Alaniz LD, Cordo Russo RI, Alvarez E and Hajos SE: PI3K/Akt inhibition modulates multidrug resistance and activates NF-κB in murine lymphoma cell lines. Leuk Res 33: 288-296, 2009.
25. Filipits M: Mechanisms of cancer: multidrug resistance. Drug Discov Today Dis Mech 1: 229-234, 2004.
26. Kuo MT, Liu Z, Wei Y, Lin-Lee YC, Tatebe S, Mills GB and Unate H: Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-κB signaling. Oncogene 21: 1945-1954, 2002. (Pubitemid 34270883)
27. Barancík M, Bohácová V, Sedlák J, Sulová Z and Breier A: LY294,002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci 29: 426-434, 2006. (Pubitemid 44709864)
28. Gill PK, Gescher A and Gant TW: Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes α and θ. Eur J Biochem 268: 4151-4157, 2001. (Pubitemid 32862875)
29. Vertegaal AC, Kuiperij HB, Yamaoka S, Courtois G, van der Eb AJ and Zantema A: Protein kinase C-α is an upstream activator of the IκB kinase complex in the TPA signal transduction pathway to NF-κB in U2OS cells. Cell Signal 12: 759-768, 2000. (Pubitemid 32056344)
30. Chao X, Zao J, Xiao-Yi G, Li-Jun M and Tao S: Blocking of PI3K/AKT induces apoptosis by its effect on NF-κB activity in gastric carcinoma cell line SGC7901. Biomed Pharmacother 64: 600-604, 2010.
31. Engelman JA: Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9: 550-562, 2009.
32. Nuutinen U, Postila V, Mättö M, Eeva J, Ropponen A, Eray M, Riikonen P and Pelkonen J: Inhibition of PI3-kinase-Akt pathway enhances dexamethasone-induced apoptosis in a human follicular lymphoma cell line. Exp Cell Res 312: 322-330, 2006. (Pubitemid 41814841)
33. Ghobrial IM, Witzig TE and Adjei AA: Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 55: 178-194, 2005. (Pubitemid 40826487)
34. Fulda S and Debatin KM: Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25: 4798-4811, 2006. (Pubitemid 44187627)
35. Riedl SJ and Salvesen GS: The apoptosome: signalling platform of cell death. Nat Rev Mol Cell Biol 8: 405-413, 2007. (Pubitemid 46643237)
36. Elumalai P, Gunadharini DN, Senthilkumar K, Banudevi S, Arunkumar R, Benson CS, Sharmila G and Arunakaran J: Induction of apoptosis in human breast cancer cells by nimbolide through extrinsic and intrinsic pathway. Toxicol Lett 215: 131-142, 2012.
37. Gillings AS, Balmanno K, Wiggins CM, Johnson M and Cook SJ: Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics. FEBS J 276: 6050-6062, 2009.
38. Tait SW and Green DR: Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 11: 621-632, 2010.
39. Kaufmann T, Strasser A and Jost PJ: Fas death receptor signalling: roles of Bid and XIAP. Cell Death Differ 19: 42-50, 2012.
40. Hussain AR, Ahmed SO, Ahmed M, Khan OS, Al Abdulmohsen S, Platanias LC, Al-Kuraya KS and Uddin S: Cross-talk between NFκB and the PI3-kinase/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis. PLoS One 7: e39945, 2012.
41. Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424-430, 2006. (Pubitemid 44050136)
42. Nicholson KM and Anderson NG: The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14: 381-395, 2002. (Pubitemid 34214843)
43. Shant J, Cheng K, Marasa BS, Wang JY and Raufman JP: Akt-dependent NF-κB activation is required for bile acids to rescue colon cancer cells from stress-induced apoptosis. Exp Cell Res 315: 432-450, 2009.
44. Uchida M, Iwase M, Takaoka S, Yoshiba S, Kondo G, Watanabe H, Ohashi M, Nagumo M and Shintani S: Enhanced susceptibility to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in oral squamous cell carcinoma cells treated with phosphatidylinositol 3-kinase inhibitors. Int J Oncol 30: 1163-1171, 2007.
45. Mantovani I, Cappellini A, Tazzari PL, Papa V, Cocco L and Martelli AM: Caspase-dependent cleavage of 170-kDa P-glycoprotein during apoptosis of human T-lymphoblastoid CEM cells. J Cell Physiol 207: 836-844, 2006. (Pubitemid 43668249)
46. McDonald GT, Sullivan R, Paré GC and Graham CH: Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression. Exp Cell Res 316: 3197-3206, 2010.
47. Shingu T, Yamada K, Hara N, Moritake K, Osago H, Terashima M, Uemura T, Yamasaki T and Tsuchiya M: Growth inhibition of human malignant glioma cells induced by the PI3-K-specific inhibitor. J Neurosurg 98: 154-161, 2003. (Pubitemid 36050459)